Production of [(18)F]DPA-714, [(18)F]fallypride and [(18)F]LBT-999 using iMiDEV, a fully automated microfluidic platform: towards clinical radiopharmaceutical production

利用全自动微流控平台iMiDEV生产[(18)F]DPA-714、[(18)F]fallypride和[(18)F]LBT-999:迈向临床放射性药物生产

阅读:2

Abstract

BACKGROUND: Positron emission tomography is widely used to study biological processes without disrupting normal physiological functions. Traditional radiotracer synthesis and industrial market is focused on producing large batches of (18)F-labelled tracers, especially [(18)F]FDG. Accessibility to smaller quantity of diverse radiopharmaceuticals is a key to enable a more personalised approach in nuclear medicine. A novel microfluidic module, iMiDEV™, has earlier been shown to be a versatile labelling platform as it has been used in the production of Na[(18)F]F and various (11)C- and (68) Ga-labelled tracers. In the current study our aim was to utilise iMiDEV™ in the synthesis of fluorine-18-labelled radiotracers, specifically [(18)F]DPA-714, [(18)F]LBT-999 and [(18)F]fallypride. RESULTS: [(18)F]DPA-714, [(18)F]LBT-999 and [(18)F]fallypride have been produced in up to 24%, 12% and 11% radiochemical yield, respectively, using the microfluidics based iMiDEV™ labelling platform. Activity yields at the end of synthesis were 3.6 GBq, 2.1 GBq and 2.3 GBq, respectively. All individual synthesis steps were studied for efficient activity transfer and labelling and the optimised synthesis sequence was fully automated. CONCLUSION: In this paper, we have demonstrated fully automated production of different (18)F-tracers of clinical relevance with moderate to good yields using microfluidic iMiDEV™ platform. Our work is a step towards more personalised, dose-on-demand manufacturing of PET radiopharmaceuticals.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。